Generation Bio to Participate in 21st Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Generation Bio Co. (Nasdaq: GBIO) announced that its CEO, Geoff McDonough, will participate in the 21st Annual Needham Virtual Healthcare Conference on April 11th at 11:00 a.m. ET. A live webcast of the event will be available on the company’s investor website, with a replay accessible for 30 days post-event. Generation Bio focuses on developing innovative genetic medicines for rare and prevalent diseases, utilizing its proprietary non-viral genetic medicine platform, which includes unique delivery systems and manufacturing processes aimed at providing durable and scalable treatments.

CAMBRIDGE, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Monday, April 11th at 11:00 a.m. ET.

A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.

About Generation Bio
Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral genetic medicine platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific cell types, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio’s manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.

For more information, please visit www.generationbio.com. 

Contact:

Investors 
Maren Killackey
Generation Bio
mkillackey@generationbio.com
857-371-4638

Media 
Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
617-903-8783

FAQ

What is the date of Generation Bio's participation in the Needham Virtual Healthcare Conference?

Generation Bio will participate in the Needham Virtual Healthcare Conference on April 11, 2022.

Who from Generation Bio will speak at the Needham Virtual Healthcare Conference?

Geoff McDonough, M.D., the CEO of Generation Bio, will speak at the conference.

Where can I watch the Generation Bio presentation at the healthcare conference?

The presentation will be available via live webcast on Generation Bio's investor website.

How long will the replay of Generation Bio's conference presentation be available?

The replay of the presentation will be accessible for 30 days following the event.

What innovative technologies does Generation Bio use for genetic medicine?

Generation Bio utilizes a unique platform that includes closed-ended DNA (ceDNA), cell-targeted lipid nanoparticles (ctLNP), and a proprietary rapid enzymatic synthesis manufacturing process.